Haugen Christine E, Patel Suhani S, Quillin Ralph C, Shah Shimul A, Chang Alex, Segev Dorry L, Massie Allan B, Orandi Babak J
Department of Surgery, University of Cincinnati, Cincinnati, OH, United States.
Department of Surgery, New York University, New York, NY, United States.
J Gastrointest Surg. 2025 Jul;29(7):102071. doi: 10.1016/j.gassur.2025.102071. Epub 2025 Apr 23.
The prevalence of obesity has dramatically increased. Candidates with obesity have higher waitlist mortality and are less likely to undergo liver transplantation (LT). The association of obesity with post-transplant mortality is inconsistent.
This study quantified the temporal trends in waitlist and transplant outcomes among patients with obesity using 2013-2023 SRTR data. Obesity class was defined as follows: no obesity (body mass index [BMI] of 18.5-29.0 kg/m), class I obesity (BMI of 30.0-34.0 kg/m), class II obesity (BMI of 35.0-39.0 kg/m), and class III obesity (BMI of 40.0-55.0 kg/m). The risks of waitlist and post-transplant mortality were quantified using adjusted competing risks and Cox proportional hazards.
Among 103,640 candidates and 58,692 recipients, candidates with higher obesity classes had higher listing Model for End-Stage Liver Disease (MELD) scores that increased over time. Candidates with class III obesity were listed and transplanted at higher MELD scores than those without obesity, those with class I obesity, and those with II obesity. Nearly 40% of candidates with class III obesity had listing MELD scores of ≥30. From 2013-2017 to 2018-2023, the waitlist mortality decreased by 35% in candidates with class III obesity (subhazard ratio, 0.65 [95% CI, 0.58-0.73]; P <.001), and post-transplant mortality decreased by 20% for recipients with class III obesity (hazard ratio, 0.80 [95% CI, 0.66-0.96]; P =.02). However, over time, post-transplant mortality differed by obesity class, with no reduction in post-transplant mortality among recipients with class I or II obesity.
LT candidates and recipients with class III obesity are being listed and transplanted at higher MELD scores with improvement in outcomes over time. Despite the higher risk, temporal trends in LT outcomes for this population are favorable. Given the higher disease severity at listing for candidates with class III obesity, referral patterns for LT evaluation in these patients should be evaluated.
肥胖症的患病率急剧上升。肥胖的候选者等待名单上的死亡率更高,且接受肝移植(LT)的可能性更小。肥胖与移植后死亡率之间的关联并不一致。
本研究使用2013 - 2023年SRTR数据量化了肥胖患者等待名单和移植结果的时间趋势。肥胖类别定义如下:无肥胖(体重指数[BMI]为18.5 - 29.0kg/m),I类肥胖(BMI为30.0 - 34.0kg/m),II类肥胖(BMI为35.0 - 39.0kg/m),III类肥胖(BMI为40.0 - 55.0kg/m)。使用调整后的竞争风险和Cox比例风险模型量化等待名单和移植后死亡的风险。
在103,640名候选者和58,692名接受者中,肥胖类别较高的候选者终末期肝病模型(MELD)评分更高,且随时间增加。III类肥胖的候选者比无肥胖者、I类肥胖者和II类肥胖者在更高的MELD评分下被列入名单并接受移植。近40%的III类肥胖候选者的MELD评分≥30。从2013 - 2017年到2018 - 2023年,III类肥胖候选者的等待名单死亡率下降了35%(亚风险比,0.65[95%CI,0.58 - 0.73];P <.001),III类肥胖接受者的移植后死亡率下降了20%(风险比,0.80[95%CI,0.66 - 0.96];P =.02)。然而,随着时间的推移,移植后死亡率因肥胖类别而异,I类或II类肥胖接受者的移植后死亡率没有下降。
III类肥胖的LT候选者和接受者在更高的MELD评分下被列入名单并接受移植,随着时间推移结果有所改善。尽管风险较高,但该人群LT结果的时间趋势是有利的。鉴于III类肥胖候选者在列入名单时疾病严重程度较高,应评估这些患者LT评估的转诊模式。